Skip to content

Stem Cell Transplant Shows Promise in Restoring Vision for Corneal Damage Patients

๐’๐ญ๐ž๐ฆ ๐‚๐ž๐ฅ๐ฅ ๐“๐ซ๐š๐ง๐ฌ๐ฉ๐ฅ๐š๐ง๐ญ ๐’๐ก๐จ๐ฐ๐ฌ ๐๐ซ๐จ๐ฆ๐ข๐ฌ๐ž ๐ข๐ง ๐‘๐ž๐ฌ๐ญ๐จ๐ซ๐ข๐ง๐  ๐•๐ข๐ฌ๐ข๐จ๐ง ๐Ÿ๐จ๐ซ ๐‚๐จ๐ซ๐ง๐ž๐š๐ฅ ๐ƒ๐š๐ฆ๐š๐ ๐ž ๐๐š๐ญ๐ข๐ž๐ง๐ญ๐ฌ.

๐Ÿ‘ A recent study published in The Lancet has shown promising results for stem cell therapy in treating patients with corneal damage. Researchers at Osaka University Hospital used corneal epithelial cell sheets derived from human induced pluripotent stem cells (iPSCs) to treat four patients with limbal stem-cell deficiency (LSCD).

๐Ÿ˜€ The results were encouraging: all patients showed improved vision and reduced corneal opacity after a year, with no significant adverse effects. This breakthrough paves the way for further research, including larger clinical trials to assess the potential of iPSCs as a treatment for LSCD.